Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

269.40CHF
22 Mar 2019
Change (% chg)

CHF-1.25 (-0.46%)
Prev Close
CHF270.65
Open
CHF270.95
Day's High
CHF272.20
Day's Low
CHF268.40
Volume
1,306,265
Avg. Vol
1,889,470
52-wk High
CHF280.55
52-wk Low
CHF206.35

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.97
Market Cap(Mil.): CHF214,033.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.31

Financials

  ROG.S Industry Sector
P/E (TTM): 22.03 29.30 32.54
EPS (TTM): 11.25 -- --
ROI: 20.46 14.23 13.82
ROE: 46.88 15.46 15.25

U.S. FDA approves Roche's small cell lung cancer treatment

March 18 Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.

19 Mar 2019

BRIEF-Roche Presents Results Of Tecentriq Study

* ROCHE TO PRESENT RESULTS OF THE LARGEST SAFETY STUDY OF ITS KIND WITH TECENTRIQ (ATEZOLIZUMAB) IN PATIENTS WITH METASTATIC BLADDER CANCER

18 Mar 2019

BRIEF-European Commission Approves Roche's Mabthera (Rituximab) For Rare Autoimmune Disease

* EUROPEAN COMMISSION APPROVES ROCHE'S MABTHERA (RITUXIMAB) FOR A RARE AUTOIMMUNE DISEASE Source text for Eikon: Further company coverage: (Reporting by Riham Alkousaa)

15 Mar 2019

BRIEF-EU Approves Roche's Hemlibra For Certain Haemophilia Patients

* EUROPEAN COMMISSION APPROVES ROCHE'S HEMLIBRA FOR PEOPLE WITH SEVERE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

14 Mar 2019

Lilly's combo therapy succeeds in late-stage lung cancer study

Eli Lilly and Co's combination cancer treatment met the main goal of a late-stage clinical trial testing it on patients with a form of lung cancer, the drugmaker announced on Tuesday.

12 Mar 2019

Lilly's combo treatment meets main goal in lung cancer late-stage study

March 12 Eli Lilly and Co said on Tuesday that its combo treatment, Cyramza, met the main goal in a late-stage study in patients with a form of lung cancer.

12 Mar 2019

BRIEF-Roche Says All Proposals Of Board Of Directors Approved In AGM

* 32TH CONSECUTIVE DIVIDEND INCREASE TO CHF 8.70 PER SHARE APPROVED

05 Mar 2019

Wall Street rises after Trump stirs China trade hopes again

NEW YORK Wall Street's three major indexes ended higher on Monday but well below the session's highs after President Donald Trump said he would delay a planned hike in tariffs on Chinese imports. | Video

25 Feb 2019

US STOCKS-Wall St rises after Trump stirs China trade hopes again

* Indexes up: Dow 0.23 pct, S&P 500 0.12 pct, Nasdaq 0.36 pct (Updates to close of trading, adds comments)

25 Feb 2019

US STOCKS-Trump talk that U.S.-China trade deal near pushes Wall St higher

* Indexes up: Dow 0.52 pct, S&P 500 0.37 pct, Nasdaq 0.56 pct (Updates to late afternoon, adds comments, changes byline, Adds New York dateline)

25 Feb 2019

Earnings vs. Estimates